info@biomedres.us
+1 (502) 904-2126
One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA
Site Map
ISSN: 2574 -1241
ISSN: 2574 -1241
Received: May 07, 2018; Published: May 14,2018
DOI: 10.26717/BJSTR.2018.04.001066
LMWH is recommended by major consensus guidelines for both initial and long-term anticoagulation in cancer-associated thrombosis. With improvements in imaging technology and extended survival duration of cancer patients, more unique challenges are encountering. These include optimal duration of anticoagulant therapy, management of incidental VTE, identifying biomarkers that can predict recurrent VTE, treatment of recurrent VTE after initial therapy, the treatment of patients with concurrent bleeding or those at a high risk of bleeding, management of VTE in intracranial malignancies and the limitations of the novel direct oral anticoagulants.
Abbreviation: VTE: Venous Thromboembolism; PE: Pulmonary Embolism; DOACs: Direct Oral Anticoagulants; LMWH: Low-Molecular-Weight Heparin; UFH: Un-Fractionated Heparin; CrCl: Creatinine Clearance; INR: International Normalized Ratio; ASCO: American Society of Clinical Oncology; FDA: Food and Drug Administration; VKAs: Vitamin K Antagonists; HIT: Heparin-Induced Thrombocytopenia.
International Association of Landscape Archaeology, Czech Glass Society, Czech Republic
Department of Chemistry, Semenov Institute of Chemical Physics, USSR Academy of Sciences, Moscow, Russia
Neurology, LA BioMed Research Institute, USA
Associate Professor at Department of Breast and Thyorid Surgey, Chongqing General Hospital, China
Clinical Radiologist (MD) - Department of RADIOLOGY, Cosenza Hospital, Cosenza, Italy
Full Text
PDF
